Dental management in patients receiving anticoagulation or antiplatelet treatment
-
Upload
- -
Category
Health & Medicine
-
view
704 -
download
5
description
Transcript of Dental management in patients receiving anticoagulation or antiplatelet treatment
![Page 1: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/1.jpg)
DENTAL DENTAL MANAGEMENT IN MANAGEMENT IN
PATIENTS RECEIVING PATIENTS RECEIVING ANTICOAGULATION ANTICOAGULATION OR ANTIPLATELET OR ANTIPLATELET
TREATMENTTREATMENT
IS STOPPING OF THE THERAPY REALLY
REQUIRED IN MINOR DENTAL SURGERY ?
Piti Niyomsirivanich, MD.
![Page 2: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/2.jpg)
CLINICAL SCENARIO
ผู้��ชาย 45 ปี Old CVA with AF with MR S/P MVR on warfarin 22 mg/week INR 3.0
จะถอนฟั�น ทำ�าไงดี� ? หย�ดียา warfarin ก่�อนไปีถอนฟั�น ไปีถอนฟั�นเลย
![Page 3: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/3.jpg)
CLINICAL SCENARIO
ผู้��หญิ�ง 75 ปี Previous STEMI S/P PCI Drug Eluting Stent
เมื่ !อ 6 เดี อนก่�อน
ASA 81 mg/d + Clopidogrel 75 mg/d
จะไปีถอนฟั�น ทำ�าไงดี� หย�ดียา ASA + Clopidogrel ก่�อนไปีถอนฟั�น หย�ดียา ASA ก่�อนไปีถอนฟั�น หย�ดียา Clopidogrel ก่�อนไปีถอนฟั�น ไปีถอนฟั�นไดี�เลย
![Page 4: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/4.jpg)
TUTORIAL IN ORAL ANTITHROMBOTIC THERAPY
![Page 5: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/5.jpg)
ANTITHROMBOTIC DRUGS CATEGORIZED BY PHARMACODYNAMICS
Anti thrombotic drug categories
Generic names and subgroup
Antiplatelet agents COX-1 inhibitor Aspirin
ADP receptor inhibitor: Clopidogrel ,Prasugrel ,Ticlopidine ,Ticagrelor
Gp IIb/IIIa inhibitor Abciximab ,Eptifibatide , Triofiban
Phosphodiesterase inhibitor Cilostazol , Dipyridamole
Vitamin K antagonist Warfarin , Coumarin , Dicoumarol , Phenprocoumon , Acenocoumarol
Factor Xa inhibitor Enoxaparin (SC), Fundaparinux (SC), rivaroxaban(SC)
Direct thrombin inhibitor dabigatran
Thrombolytic drugs tPAAlteplase , Tenecteplase , Reteplase , Streptokinase , UrokinaseAdapted from Cochrane Database Syst. Rev,CD 001820.
![Page 6: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/6.jpg)
OVERVIEW OF CLOT FORMATION
injury
TF ThrombinCoagulation cascade
Collagen vWF
ADP
Thromboxane A2
P2Y12
PAR-1
GP IIb/IIIa
Fibrin platelet aggregation
Xa/Va prothrominase complex
![Page 7: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/7.jpg)
OVERVIEW OF CLOT FORMATION
injury
TF ThrombinCoagulation cascade
Collagen vWF
ADP
Thromboxane A2
P2Y12
PAR-1
GP Iib/IIIa
Fibrin platelet aggregation
Xa/Va prothrominase complex
![Page 8: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/8.jpg)
CONCEPTS ON EARLY COAGULATION CASCADE
Intrinsic pathway extrinsic pathway
TF/VIIa
XI XIa
IX IXa
XaX X
XII,HMK , PK
Prothrombin(II) Thrombin
Fibinogen(I) Fibrin
PL ,VIIIa Ca PL, Ca
PL ,Va Ca
Adapted from Thromb Haemost 85(6):958-65
![Page 9: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/9.jpg)
CONCEPTS ON EARLY COAGULATION CASCADE
Intrinsic pathway extrinsic pathway
TF/VIIa
XI XIa
IX IXa
XaX X
XII,HMK , PK
Prothrombin(II) Thrombin
Fibinogen(I) Fibrin
VKA e.g. warfarin
Inh. II , VII ,IX ,X
PL ,VIIIa Ca PL, Ca
PL ,Va Ca
Adapted from Thromb Haemost 85(6):958-65
![Page 10: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/10.jpg)
CONCEPTS ON EARLY COAGULATION CASCADE
Intrinsic pathway extrinsic pathway
XI XIa
Xa
XII,HMK , PK
Fibinogen(I) Fibrin
Factor Xa inhibitor : Enoxaparin ,
Fundaparinux
PL ,VIIIa Ca PL, Ca
PL ,Va Ca
TF/VIIaIX IXa
Prothrombin(II) Thrombin
Adapted from Thromb Haemost 85(6):958-65
X X
![Page 11: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/11.jpg)
CONCEPTS ON EARLY COAGULATION CASCADE
Intrinsic pathway extrinsic pathway
XI XIa
XII,HMK , PK
Fibinogen(I) Fibrin
Direct thrombin inhibitor :
dabigatran
PL ,VIIIa Ca PL, Ca
PL ,Va Ca
TF/VIIaIX IXa
Prothrombin(II) Thrombin
XaX X
Adapted from Thromb Haemost 85(6):958-65
![Page 12: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/12.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
Initiation
TF –bearing celle.g. fibroblast TF
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 13: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/13.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
Initiation
TF –bearing celle.g. fibroblast TF
VII
VIIa
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 14: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/14.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
Initiation
TF –bearing celle.g. fibroblast TF
VIIa
TF/VII complex
X
Xa
IX
IXa
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 15: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/15.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
Initiation
TF –bearing celle.g. fibroblast TF
VIIa
TF/VII complex
IXa
Xa/Va complex
VaXa
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 16: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/16.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
Amplification
TF –bearing celle.g. fibroblast TF
VIIa
TF/VII complexVaXa
IXa
Xa/Va complex
prothrombin
Thrombin
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 17: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/17.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
AmplificationTF –
bearing celle.g.
fibroblast
TF
VIIa
Va
Xa
IXa
Thrombin
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 18: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/18.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
AmplificationTF –
bearing celle.g.
fibroblast
TF
VIIa
Va
Xa
Thrombin
Platelet Activation
VaV
vWF/VIII
VIIIa
IXa
IX
PAR1,PAR4
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
Thromboxane A2 synthesis
![Page 19: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/19.jpg)
CONCEPTS ON THE NEW, CELL-BASED COAGULATION MODEL
PropagationTF –
bearing celle.g.
fibroblast
TF
VIIa
Va
Xa
Activated Platelet
Va
VIIIa IXa
Intrinsic tenase
X Xa
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 20: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/20.jpg)
CONCEPS ON THE NEW, CELL-BASED COAGULATION MODEL
PropagationTF –
bearing celle.g.
fibroblast
TF
VIIa
Va
Xa
Activated Platelet
Va
VIIIa IXa
Intrinsic tenase
XaVa/Xa complex(Prothrombinase)
Fibrinogen Fibrin
Prothrombin Thrombin
Adapted from Thromb Haemost 85(6):958-65Arterioscler Thromb Vasc Biol 2006:26(1):41-8
![Page 21: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/21.jpg)
PRE-OPERATIVE EVALUATION FOR ANTICOAGULANTS
Bleeding Risk Procedure
Versus
Risk of thromboembolic events
Whether to off anticoagulants ?
![Page 22: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/22.jpg)
PATIENT VERSUS SURGICAL RISK FACTORS
Patient Risk Factors
Prior thromboembolism ?
Mechanical valve ?
AF ?
Surgical Risk Factors
Procedure type ? Quantify Risk of
bleeding ?
Quantify Risk of thromboembolism ?
![Page 23: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/23.jpg)
RISK OF THROMBOEMBOLISM
Michael et al. After discontinue OAT in 169 patients 22% thromboembolic event 7% died
Tulloch and Wright et al. Case Report Discontinue OAT for 8 days before oral surgery Post operative day 2 CVA Post operative day 4 branchial artery emboli
Br Heart J 1970;32:359-364Circulation 1954;9:823-834
![Page 24: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/24.jpg)
RISK OF THROMBOEMBOLISM
Wahl et al. Review > 2400 cases 950 cases continued oral antithrombotic
12 cases experienced post-operative bleeding Which controlled by local measures
Incidence of thromboembolic complication was about 1%
Small but outcome serious !!!
Arch Intern Med 1998;158:1610-1616
![Page 25: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/25.jpg)
RISK OF HEMORRHAGE
Cambell et al. Randomized controlled trial Continue OAT versus withdrawn OAT No significant difference in total blood loss
Madrid and Sanz Systemic review Continue OAT with INR 2-4 and discontinue OAT No significant in post operative hemorrhage
J oral Maxillofac Surg 2000;58:131-135Clin Oral Implants Res 2009;20 Suppl 4:96-106
![Page 26: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/26.jpg)
MEANING OF INR VALUE
Most anticoagulation therapyINR 2.0 - 3.0
Few INR 3.0 - 4.0
Blinder et al. INR value did not significantly influence the
incident of perioperative bleeding (INR 2.0 -4.0)
INR 2.0-4.0 post operative hemorrhage can not be so serious
Int J Oral Maxillo Surg 2008;66:51-57
![Page 27: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/27.jpg)
CONCLUSION
ThromboembolisThromboembolism Riskm Risk
Bleeding Risk
Local control
Small but outcome serious !!! Arch Intern Med 1998;158:1610-1616
![Page 28: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/28.jpg)
CHEST 2012; 141:326-350S
![Page 29: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/29.jpg)
CLINICAL SCENARIO
ผู้��ชาย 45 ปี Old CVA with AF with MR S/P MVR on warfarin 22 mg/week INR 3.0
จะถอนฟั�น ทำ�าไงดี� ? หย�ดียา warfarin ก่�อนไปีถอนฟั�น ไปีถอนฟั�นเลย
![Page 30: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/30.jpg)
OVERVIEW OF CLOT FORMATION
injury
TF ThrombinCoagulation cascade
Collagen vWF
ADP
Thromboxane A2
P2Y12
PPAR-1
GP Iib/IIIa
Fibrin platelet aggregation
Xa/Va prothrominase complex
![Page 31: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/31.jpg)
ANTIPLATELET
promote
vWFvWF
![Page 32: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/32.jpg)
ASPIRIN ARACHIDONIC ACID METABOLISM
Phospholipid-Arachidonic acid
Phospholipases
Arachidonic acid
Prostaglandin G2
Prostaglandin H2
Tissue Specific Isomerases
COX1
HOX
Arachidonic acid
Prostaglandin G2
Prostaglandin H2
COX2
HOX
Thromboxane A2(Promote Thrombosis)
Prostaglandin D2 Prostaglandin E2 Prostaglandin F2aProstacyclin(inhibit Plt aggregation)
Low dose ASA High dose ASA(Inflammatory dose)
Higher dose block
Adapted from: CHEST 2012; 141(2) (Suppl) : e89S-e119S
Platelets & vascular endothelial cells
![Page 33: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/33.jpg)
Dipyridamole. effects of dipyridamole on NO/cGMP and prostaglandin/cAMP signal transduction in human
platelets.
Adapted from :Aktas B et al. Stroke. 2003;34:764-769
Copyright © American Heart Association, Inc. All rights reserved.
Platelet aggregation Platelet aggregation
![Page 34: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/34.jpg)
DIPYRIDAMOLE.PROMOTE PROSTACYCLIN
promote
![Page 35: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/35.jpg)
CILOSTAZOL PHOSPHODIESTERASE III INHIBITORS
Eur Heart J (2008) 29 (18): 2202-2211.
Vasodilatory stimulating phosphoprotein
![Page 36: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/36.jpg)
THIENOPYRIDINESTICLOPIDINE ,CLOPIDOGREL , PRASUGREL
Eur Heart J (2008) 29 (18): 2202-2211.
![Page 37: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/37.jpg)
ANTIPLATELET AND ORAL SURGERY
Ardekian et al. 39 patients taking ASA 100 mg
19 continued20 stopped
Bleeding time 3.1 min versus 1.8 min (p=0.004)
None of them had prolong bleeding time >10 min
No patient experienced uncontrolled bleeding Antiplatelet should not be discontinued prior to
dental procedureJ Am Dent Assoc 131,331-335
![Page 38: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/38.jpg)
DUAL ANTIPLATELET OR SINGLE ANTIPLATELET?
Nepanas et al. Retrospective study 43 patients who were receiving single or dual
antiplatelet therapy
Twenty-nine patients (67 percent) were receiving dual antiplatelet therapy.
The authors found no differences between patients receiving single or dual antiplatelet therapy for all variables.
J Am Dent Assoc. 2009 Jun;140(6):690-5
![Page 39: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/39.jpg)
COMPLICATION RATES FROM DISCONTINUATION OF ANTIPLATELETE < 6 WKS AFTER PCI W/WO STENT
![Page 40: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/40.jpg)
CHEST 2012; 141:326-350S
![Page 41: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/41.jpg)
CLINICAL SCENARIO
ผู้��หญิ�ง 75 ปี Previous STEMI S/P PCI Drug Eluting Stent
เมื่ !อ 6 เดี อนก่�อน
ASA 81 mg/d + Clopidogrel 75 mg/d
จะไปีถอนฟั�น ทำ�าไงดี� หย�ดียา ASA + Clopidogrel ก่�อนไปีถอนฟั�น หย�ดียา ASA ก่�อนไปีถอนฟั�น หย�ดียา Clopidogrel ก่�อนไปีถอนฟั�น ไปีถอนฟั�นไดี�เลย
![Page 42: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/42.jpg)
CLINICAL SCENARIO
ผู้��หญิ�ง 75 ปี Previous STEMI S/P PCI Drug Eluting Stent
เมื่ !อ 6 เดี อนก่�อน
ASA 81 mg/d + Clopidogrel 75 mg/d
จะไปีถอนฟั�น ทำ�าไงดี� หย�ดียา ASA + Clopidogrel ก่�อนไปีถอนฟั�น หย�ดียา ASA ก่�อนไปีถอนฟั�น หย�ดียา Clopidogrel ก่�อนไปีถอนฟั�น ไปีถอนฟั�นไดี�เลย
![Page 43: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/43.jpg)
LOCAL BLEEDING CONTROL
Local anesthesia with vasoconstrictor Local hemostatic material (bonewax ,surgicel) Local hemostatic agent (epinephrine solution )
Suture Pressure Dressing Peridontal pack application Tranexamic acid Mouth wash
Journal of Oral Science,Vol.49,No.4,253-258,2007
![Page 44: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/44.jpg)
TAKE HOME MESSAGE Warfarin
ถ�า INR 2 - 4 ไมื่�ต้�องหย�ดี
ถ�า INR > 4 ไมื่�ต้�องผู้�า/ทำ�าฟั�นทำ�ก่ก่รณี�
Antiplatelets ASA , clopidogrel ,prasugrel , ticlopidine ,
cilostazole , Tegagrelor etc.
ไมื่�ต้�องหย�ดีทำ�ก่รณี� ไมื่�ว่�าจะ on ดี�ว่ย indication primary prevention , secondary prevention , S/P stent ก่&ต้ามื่ ทำ'(ง single หร อ dual antiplatelet
![Page 45: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/45.jpg)
HIGH ALERT DON’T STOP OAT!!!
Warfarin Mechanical valve , Hypercoagulable state
Antiplatelet S/P w Stent [DES , BMS] within 1 years
![Page 46: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/46.jpg)
สุ�ดีทำ�าย
หาก่ INR สุองถ*งสุ�!น' (น บ่�หย�ดีINR เก่�น 4 ให� ผู้�าไมื่�antiplatelet ไซร� อย�าไดี�
หย�ดีเลยบ่�หย�ดีOATไว่� จ'ก่ไดี�
ปีลอดีภั'ย
![Page 47: Dental management in patients receiving anticoagulation or antiplatelet treatment](https://reader033.fdocuments.net/reader033/viewer/2022052410/554b9dcfb4c905ae618b4788/html5/thumbnails/47.jpg)
THANK YOU